Research Highlights:
- A widely used heart failure medication called sacubitril/valsartan was associated with a lower risk of heart damage compared to placebo among high-risk cancer patients being treated with anthracycline chemotherapy agents.
- The risk of cardiomyopathy among high-risk cancer patients treated with anthracyclines who took sacubitril/valsartan decreased by 77% compared to those taking a placebo.
- Participants began with a 24/26 mg dose of sacubitril/valsartan twice daily, which was titrated every two weeks until they reached a target dose of 97/103 mg twice daily, or the highest dose that patients were able to tolerate without side effects. The medication was generally well tolerated, the researchers noted.
- Note: The study featured in this news release is a research abstract. Abstracts presented at American Heart Association's scientific meetings are not peer-reviewed, and the findings are considered preliminary until published as full manuscripts in a peer-reviewed scientific journal.
This news release contains updated information from the researcher that was not in the abstract.
CHICAGO, Nov. 18, 2024 — A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association's Scientific Sessions 2024. The meeting, Nov. 16-18, 2024, in Chicago, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science.
"We have identified a promising new strategy for protecting the heart during cancer treatment, with the potential to impact patient care significantly and future research in heart disease and cancer," said study lead author Marcely Bonatto, M.D., a cardiologist and specialist in heart failure and heart transplantation at the Heart Institute, University of São Paulo in Curitiba, Brazil. "Importantly, our strategy enables early identification of people at high risk for developing heart dysfunction, allowing for timely interventions to prevent further loss of heart function."
Heart failure occurs when damage prevents the heart from pumping blood well enough to supply the body with blood and nutrients. Anthracyclines are a class of chemotherapy medications used to treat many types of cancer, including breast cancer, leukemia, lymphoma and sarcoma. However, one of their potential side effects is cardiomyopathy, a disease of the heart muscle that makes it harder for the heart to pump blood to the rest of the body. Cardiomyopathy is a form of cardiotoxicity that refers to heart damage caused by cancer treatments involving chemotherapy.
The SARAH clinical trial examined the effects of the heart-failure medication sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor or ARNI, on preventing further heart damage among 114 patients undergoing chemotherapy treatment with anthracyclines for breast cancer, lymphoma, sarcoma or leukemia.
The study found:
- Compared to a placebo, sacubitril/valsartan was associated with a 77% decrease in relative risk of further heart damage among people who already had signs of damage. Patients' reduction in the incidence of cardiotoxicity was assessed from the moment treatment began until the end of the intervention—at 24 weeks.
- Participants began with a 24/26 mg dose of sacubitril/valsartan twice daily, which was titrated every two weeks until they reached a target dose of 97/103 mg twice daily, or the highest dose that patients were able to tolerate without side effects. The medication was generally well tolerated, the researchers noted.
- Compared to participants who received a placebo, those in the sacubitril/valsartan group were much less likely to develop additional heart damage by the end of the 24-week intervention period. Participants in the treatment group improved their GLS (global longitudinal strain), a marker of heart contractility, by an average of 2.55%, while participants in the placebo group experienced an average 6.65% decline in GLS.
"Our findings highlight the importance of identifying patients with high-risk who are most likely to benefit from heart protection, and therefore, minimize unnecessary side effects and health care costs for low-risk people," Bonatto said. "Accurately identifying which people will benefit from these strategies remains a significant challenge."
The study had several limitations, including that all participants were at high risk for heart damage and were receiving anthracyclines for chemotherapy—113 received doxorubicin and 1 received daunorubicin—so the findings may not apply to people with lower risk or those treated with different chemotherapy medications. Other limitations are that the study could not account for heart damage after the six-month follow-up and did not look at other factors like survival or quality of life. The study also took place in a single hospital in Brazil, so the findings may not apply to patients treated in other hospitals. Additional research is needed on more diverse patient groups because the study participants were mostly white and female.
Study background and details:
- The SARAH trial included 114 adults with cancer undergoing chemotherapy at Erasto Gaertner, a cancer hospital in Curitiba, Brazil. 80.7% were being treated for breast cancer; 16.7 for leukemia; 1.7% for sarcoma and 0.9% for leukemia.
- The average age of participants was 52 years, and 90% of study participants self-identified as women, and 10% self-identified as men. 92% of participants self-identified as white adults; 7% as Black or mixed-race (Pardo) adults and 1% as Asian adults.
- All participants were considered high-risk due to existing heart damage, defined by high levels of troponin in the blood, a protein that the heart releases when damaged.
- Participants underwent periodic clinical examinations, including blood testing and specialized heart testing with echocardiography and cardiac MRI (magnetic resonance imaging) for six months to assess heart damage and changes in function.
- The study was conducted from March 2022 to August 2024.
Co-authors, disclosures and funding sources are listed in the manuscript.
Statements and conclusions of studies that are presented at the American Heart Association's scientific meetings are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association's scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
